Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : lcav -- Ignore unavailable to you. Want to Upgrade?

To: Manny Gugliuzza who wrote (575)	11/24/1998 12:04:00 PM
From: BARRY ALLEN	Read Replies (1) \| Respond to of 942

LCA-VISION INTRODUCES NEW 'CONTINUUM OF CARE' LIFETIME PROGRAM; Expected To Build Consumer Confidence, Boost Patient Volume Business Wire - November 24, 1998 10:32 CINCINNATI--(BUSINESS WIRE)--November 24, 1998--In a major move reflecting confidence in the long-term efficacy and visual stability of laser vision correction, LCA-Vision Inc. (NASDAQ:LCAV) today introduced its new "Continuum of Care" program that provides lifetime care to most patients undergoing laser treatment to correct myopia, astigmatism, or hyperopia. Commenting on the ground-breaking program, LCA-Vision Chairman and CEO Dr. Stephen Joffe said: "Our willingness to make this commitment, extending care from the usual 12-month post-operative period to a patient's lifetime, underscores the excellent results LCA-Vision has achieved performing nearly 40,000 procedures over the last seven years. The 'Continuum of Care' is a powerful incentive that will give a significant boost to our marketing efforts and give potential patients greater confidence to undergo laser vision correction." To participate in the program, Dr. Joffe explained, the patient and the LCA-Vision medical team will agree on the level of correction to be achieved and which laser refractive technique will produce the best results. In those very few instances when the desired correction is not achieved in the initial procedure, and the team believes a second procedure is likely to improve the visual outcome, the patient will be re-treated. The program also provides that, if at any time during a patient's lifetime, his, or her, vision drops below the desired level, re-treatment will be provided as long as the patient has had the necessary annual check-up and the problem "is related to myopic regression or refractive error caused by natural physiological conditions." The decision to re-treat will be made jointly by the treating LCA-Vision surgeon, the patient, and the co-managing doctor. To maintain eligibility in "Continuum of Care," patients must return to their affiliated physician (MD or OD) for an annual eye examination. Patients with extreme degrees of pathological myopia and astigmatism may not qualify. LCA-Vision operates 22 laser vision correction centers in the U.S., Canada and Europe. The number of laser surgery procedures performed at those facilities is now close to 40,000. Additionally, LCA-Vision also manages laser, and other minimally invasive, surgical programs. CONTACT: Dr. Stephen Joffe, CEO Ken DiPaola or Joel Pomerantz LCA-Vision Inc. The Dilenschneider Group (513) 792-9292 (212) 922-0900